ALK and lung carcinoma: Since Poziotinib was initially developed as an effective drug to treat lung cancer with HER2 mutation53, this context appears to be reflected in the embeddings, as ROS1 and EML4-ALK fusion genes are also characteristic mutations and therapeutic targets in lung cancer54,55.